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Cancer is the number two killer in the 
United States and will probably account for 
some 400,000 deaths in 1982 . The lung has 
now achieved the dubious distinction of being 
the most common site of cancer in men and 
causes the most deaths. Cancer of the colon 
and rectum is the second most common cancer 
in both males and females combined, whereas 
carcinoma of the breast and uterus pre-
dominate in women. 
The incidence of most cancers has been 
rising rather slowly over the past several dec-
ades for reasons that are not clear, possibly be-
cause of increasing contamination of our envi-
ronment by chemical carcinogens, air pollution, 
and prescription drugs. In males lung cancer 
has dwarfed the incidence of most of the other 
tumors; even in females there is an ominous re-
cent sharp angling of the curve upward . Carci-
noma of the stomach and carcinoma of the cer-
vix have markedly declined during the past 
several years, but the reason for this is unclear. 
Perhaps the decline may be related to some 
dietary factor which has been eliminated due to 
better techniques for preserving or preparing 
meat. 
It is useful to examine the anticipated five-
year cancer survival rates for specific sites 
taken from the Surveillance Epidemiology End 
Results Group of the National Cancer Institute. 
Many localized cancers, particulary those of the 
bladder, breast , colon , larynx, prostate and 
uterus, show prolonged survival times. The no-
table exception is the lung with a five-year sur-
vival of only 23%, even if the tumor is localized 
at the time of surgery. The American Cancer 
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Society purports to indicate that this means tu-
mors should be detected earlier . An alternative 
explanation is that those tumors which remain 
localized are biologically less malignant and 
grow more slowly, and therefore have a greater 
likelihood of being found at a time when they 
have not yet spread. 
· What is not emphasized is that for pros-
tatic neoplasms and lung cancer , probably 80-
85% of the tumors are disseminated when first 
discovered, so that the localized cancers are in 
the distinct minority. Once a tumor has been 
disseminated, the chances for prolonging sur-
vival are greatly diminished. 
During the past five years there have been 
no substantially new modalities of therapy. In 
some areas our surgical techniques are already 
extremely refined while in other areas they con-
tinue to evolve, as in the currently expanding 
use of microsurgery in pituitary, pineal , ocular, 
and laryngeal tumors. There has been a prolifer-
ation of endoscopists, and it is now a rare endo-
bronchial, colonic, or jejunal lesion that man-
ages to escape direct visual inspection through 
the endoscope befpre it is removed . 
Substantial advances have been made in 
diagnostic radiology, particularly in the areas of 
CT scanning and ultrasound . Radiotherapeutic 
techniques have gradually evolved as well. 
Treatment planning is better because of newer 
computer-simulated models. The high-voltage 
linear accelerator and the use of newer heavy 
particles, such as the neutron and photon 
beams, have also given a higher therapeutic in-
dex in specific problems. 
The cumulative impact of these refine-
ments in surgery, radiology, and chemotherapy 
has been substantial. For example, in radio-
therapy there has been great improvement in 
survival for those who have tumors that are both 
radiosensitive and tend to be localized. There is 
little question that we have markedly improved 
the therapeutic index in retinoblastoma, testicu-
lar carcinoma, Hodgkin disease, and have im-
proved the situation in head and neck cancer, 
as well as prostate, bladder, ovary, and tonsil 
cancer. 
More striking is that a number of cancers, 
particulary congenital trophoblastic tumors, Bur-
kitt lymphoma, testicular neoplasms, Wilms 
tumor, and neuroblastoma are now being cured 
routinely by chemotherapy. Hodgkin disease 
has been heavily affected by appropriately used 
radiation therapy and chemotherapy, some-
times in combination. Survival of patients with 
Hodgkin disease in 1979 is probably greater 
than 50% for all tumors. Chemotherapy is also 
generally agreed to be useful for palliation of 
prostatic carcinoma and breast carcinoma as 
well as chronic lymphocytic leukemia, lympho-
sarcoma, and acute myeloblastic leukemia. 
We have not changed survival times of pa-
tients with the more common solid tumors to 
any extent despite the progress we have made 
in controlling the fluid tumors of leukemia and 
lymphoma. Little progress has been made in 
prolonging survival of patients with solid organ 
tumors, particularly those of the lung, colon, 
and genitourinary tract which are the most com-
mon and which far outnumber leukemias and 
lymphomas. Nevertheless, a great deal of prog-
ress has been made during the past decade. 
We have learned much about the biologi-
cal behavior of human tumors, some from ani-
mal experimentation and some from carefully 
designed cooperative clinical trials. There are 
two important concepts which have had consid-
erable impact: first, the concept of micrometas-
tases and their relationship to tumor burden, 
particularly in breast cancer; and second, differ-
ences in biologic aggressiveness among histo-
logically-similar types of cancer as exemplified 
by Hodgkin disease. 
With respect to the concept of total tumor 
burden and micrometastases, it should first be 
stressed that all tumors, when discovered, are 
actually in a fairly late stage of their growth. If 
we assume that a tumor begins as a single cell 
and continues doubling and growing ex-
ponentially, it has already divided approximately 
30 times to reach a size of about 1 08 or 1 09 
cells and a weight of about one gram. A one-cm 
tumor nodule is probably at the limit of detection 
either by palpation or x-ray. 
Treatment may accomplish any of several 
goals. An effective treatment may shrink the tu-
mor drastically, perhaps by a factor of a thou-
sand, but unless every cell is destroyed, it is al-
most certain that the tumor will recur. If the 
recurrent tumor tends to follow the same kinet-
ics as the earlier tumor, its rate of growth will be 
the same. This is usually the case except in the 
case of metastatic tumors; such tumors usually 
grow faster. In general, the more substantial the 
response, the longer the survival. 
In some instances effective treatment, 
such as hormonal therapy, may drive the tumor 
into a state of dormancy or quiescence, so that 
its rate of growth is changed, but at some later 
point when it resumes autonomous growth, it 
will again grow at a rate similar to the rate it ex-
hibited initially or even faster. 
Many chemotherapists have spoken of 
eradication of the last tumor cell. We now know 
that this is somewhat naive and may perhaps 
apply to one or two tumors in which most all the 
cells are actively growing and are susceptible to 
a chemotherapeutic agent. In the most common 
solid tumors such as those of the lung, breast, 
and colon, only a portion of the cells are in 
cycle and are susceptible to chemotherapy at 
any one time. 
It is likely that many tumors continually 
shed cells into the circulation, and the cells that 
are shed must be counted in the total tumor bur-
den. There was an experiment which was per-
formed in mice in which an implanted mammary 
carcinoma was allowed to grow to the size of 
700 mg. At that time surgery was performed, 
and all visible tumor was excised. Nevertheless, 
it was clear that there must have been microme-
tastases at sites distant from the resection be-
cause with large tumors essentially no mice re-
mained tumor free one month after surgery. 
There is a striking parallelism between this 
experiment and a similar study performed in hu-
mans where the tumor burden was simply mea-
sured by the number of positive lymph nodes 
found during surgery in patients with breast car-
cinoma. As the number of positive nodes in-
creased , the ten-year survival of these patients 
fell drastically. A number of surgeons claim that 
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patients with higher numbers of positive lymph 
nodes do poorly because the nodes act as a 
secondary focus of disease and that more ex-
tensive operations should be performed. 
If this thesis were correct, then there 
should be clearly demonstrable differences be-
tween patients that had different types of opera-
tions. The newer operation that is now being 
performed is a simple or total mastectomy in 
which just the breast is removed, but the con-
tents of the axilla are not taken (they may be 
biopsied but are not removed), and the pecto-
ralis muscle is also preserved. This is to be 
compared with a standard radical mastectomy 
in which the entire contents of the axilla are re-
moved together with the pectoralis muscle, 
leaving only the intercostal muscles and the ribs 
after mastectomy. 
After five years the National Surgical Adju-
vant Breast Protocol Groups have shown no dif-
ference in survival among almost 1 ,000 pa-
tients who underwent different types of 
mastectomy. This would affirm that the reason 
for failure of breast carcinoma treatment is due 
to distant metastases which are not visible at 
the time of surgery. This concept has had an 
enormous impact on the area of breast cancer 
because it has led to trials of adjuvant chemo-
therapy which have, in fact, greatly improved 
survival where surgery could not. 
In Hogkin disease we have a similar situa-
tion but with one additional complicating factor. 
First, we do know that in Hodgkin disease the 
total body burden of the disease does bear a 
close relationship to prognosis. Early in the 
treatment of Hodgkin disease, many of the ob-
servers at Stanford and other institutions con-
cluded that most Hodgkin disease spread by 
contiguity and that the disease essentially could 
be cured if radiotherapy could be applied to all 
the involved fields plus an additional margin of 
safety around the field. Thus, Stage I could be 
treated by radiotherapy to the axilla and the me-
diastinum. 
An additional important prognostic factor 
in Hodgkin disease is the histologic type of the 
disease. Four current histologic classifications 
are recognized : lymphocytic predominance, 
nodular sclerosis, mixed cellularity, and lym-
phoid depletion. In this progression the last type 
has the most Reed-Sternberg cells, the least 
lymphocytes, and the worst prognosis, no mat-
ter what the stage. Each of these histologic pre-
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sentations is closely associated with a specific 
stage of the disease; for example, lymphoid de-
pletion is extremely rare in Stage I and is most 
found in Stage Ill or IV. On the other hand, lym-
phocytic predominance is usually found as 
Stage I or Stage II. Although there is some over-
lap between histologic patterns of the disease, 
in the main the histologic patterns tend to per-
sist for long periods of time. 
It is beginning to appear that Hodgkin dis-
ease may consist of at least four separate clini-
cal entities, each of which pursues a different 
course and for which different management 
strategies are indicated. For Hodgkin sarcoma, 
which tends to disseminate rapidly and prob-
ably does not spread by contiguity, localized ra-
diotherapy would be useless and systemic che-
motherapy would be the more effective agent. 
Similarly, for lymphocytic predominance, che-
motherapy would probably represent too much 
treatment. An important corollary has been that 
the presence of systemic symptoms indicates 
that the disease is aggressive and probably will 
also require systemic treatment . Thus, even if 
the disease is Stage II during intensive investi-
gation but systemic symptoms are present, the 
recurrence rate after radiotherapy only is high 
so that chemotherapy should be considered 
even at that early stage. 
There are other examples of tumors of dif-
ferent biologic aggressiveness. It is easy to re-
call the difference in aggressiveness, growth 
rate and prognosis in patients with estrogen-re-
ceptor positive and estrogen-receptor negative 
breast cancer. In malignant melanoma as well, 
it has become apparent that certain types of 
melanoma, particularly the lentigo maligna or 
the superficial spreading melanoma, are much 
less virulent than the nodular melanoma. This 
undoubtedly will be important at a later time in 
treatment, but as yet no effective treatment regi-
men has been designed for any of these stages. 
Another important topic for which great in-
terest has been generated during the past dec-
ade is that of the possibility of immunotherapy, 
that is to say, that of immunizing the patient 
against his own tumor. Unfortunately, this treat-
ment will also have to await the future because 
there is no firm evidence that immunizing pa-
tients with their own tumor in any way has al-
tered survival or produced regression of the dis-
ease on its own. When used in combination with 
chemotherapy, most controlled studies have not 
indicated that there is any additional benefit of 
adding immunotherapy, although the work is 
not yet completed. One of the important divi-
dends of immunotherapeutic research has been 
the notion that there are certain antigens on the 
surfaces of tumor cells which may be important 
in diagnosis and detection. 
The carcinoembryonic antigen (CEA) is a 
specific antigen which is represented on the 
surface of colonic tumors and also on the sur-
face of the fetal colon as well. The tum9r sheds 
CEA into the serum, and this can be detected 
by radioimmunoassay. Whereas CEA levels 
have not been found to be particularly useful in 
the detection and screening of coionic carci-
noma, they have been valuable for following the 
course of the patient after surgery. Typically, 
normal patients do not have CEA levels above 
five nanograms per ml; colon cancer patients 
. may have much higher levels~ If resection is 
successful and complete, the levels fall rapidly 
after operation . In 30-40% of cases, the CEA 
rises several months before recurrence is Clini-
cally detectable. 
In acute myeloblastic leukemia we have 
been carrying out similar experiments at this in-
stitution in conjunction With the University of To-
ronto, and we have been performing tests on 
bone marrow of leukemia patients in remission 
to determine whether we mjght predict relapse 
at an earlier time. Some of our data on 43 pa-
tients will soon be published in the New England 
Journal of Medicine. 
This suggests that tests can be devised 
which will pick up impending relapse in patients 
with myeloblastic leukemia approximately four 
to five months before the tumor appears in the 
bone marrow. We hope to exploit this fact by 
applying reinduction chemotherapy at an earlier 
stage. 
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